Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Stock Competitors & Peer Comparison
See JAZZ's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for JAZZ and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| JAZZ | $253.03 | +1.88% | 15.9B | 9.44 | $26.82 | N/A |
| VRTX | $542.72 | +5.27% | 134.1B | 27.76 | $19.03 | N/A |
| REGN | $838.30 | +4.02% | 83.5B | 17.76 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,023.16 | +3.58% | 61.8B | 89.62 | $11.08 | N/A |
| RVMDW | $12.59 | +4.57% | 48.8B | -1.72 | -$7.21 | N/A |
| RVMD | $217.68 | +2.68% | 45.9B | -24.49 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $378.51 | +4.41% | 39.4B | 64.99 | $5.68 | N/A |
| ALNY | $238.09 | +6.00% | 30.6B | 41.19 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
JAZZ vs VRTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, VRTX has a market cap of 134.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while VRTX trades at $542.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas VRTX's P/E ratio is 27.76. In terms of profitability, JAZZ's ROE is +0.21%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, JAZZ is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
JAZZ vs REGN Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, REGN has a market cap of 83.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while REGN trades at $838.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas REGN's P/E ratio is 17.76. In terms of profitability, JAZZ's ROE is +0.21%, compared to REGN's ROE of +0.14%. Regarding short-term risk, JAZZ is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
JAZZ vs VRNA Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas VRNA's P/E ratio is -102.80. In terms of profitability, JAZZ's ROE is +0.21%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, JAZZ is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
JAZZ vs ARGX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ARGX has a market cap of 61.8B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ARGX trades at $1,023.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ARGX's P/E ratio is 89.62. In terms of profitability, JAZZ's ROE is +0.21%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, JAZZ is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
JAZZ vs RVMDW Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, RVMDW has a market cap of 48.8B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while RVMDW trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas RVMDW's P/E ratio is -1.72. In terms of profitability, JAZZ's ROE is +0.21%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, JAZZ is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
JAZZ vs RVMD Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, RVMD has a market cap of 45.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while RVMD trades at $217.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas RVMD's P/E ratio is -24.49. In terms of profitability, JAZZ's ROE is +0.21%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, JAZZ is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
JAZZ vs SGEN Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas SGEN's P/E ratio is -57.19. In terms of profitability, JAZZ's ROE is +0.21%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, JAZZ is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
JAZZ vs ONC Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ONC has a market cap of 39.4B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ONC trades at $378.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ONC's P/E ratio is 64.99. In terms of profitability, JAZZ's ROE is +0.21%, compared to ONC's ROE of +0.14%. Regarding short-term risk, JAZZ is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
JAZZ vs ALNY Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ALNY has a market cap of 30.6B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ALNY trades at $238.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ALNY's P/E ratio is 41.19. In terms of profitability, JAZZ's ROE is +0.21%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, JAZZ is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
JAZZ vs INSM Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, INSM has a market cap of 27.8B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while INSM trades at $128.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas INSM's P/E ratio is -28.11. In terms of profitability, JAZZ's ROE is +0.21%, compared to INSM's ROE of -1.11%. Regarding short-term risk, JAZZ is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
JAZZ vs ROIV Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ROIV has a market cap of 27B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ROIV trades at $36.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ROIV's P/E ratio is -35.55. In terms of profitability, JAZZ's ROE is +0.21%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, JAZZ is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
JAZZ vs INCY Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, INCY has a market cap of 25B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while INCY trades at $126.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas INCY's P/E ratio is 16.60. In terms of profitability, JAZZ's ROE is +0.21%, compared to INCY's ROE of +0.30%. Regarding short-term risk, JAZZ is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check INCY's competition here
Moderna, Inc. (NASDAQ: MRNA)
JAZZ vs MRNA Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, MRNA has a market cap of 25B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while MRNA trades at $160.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas MRNA's P/E ratio is -7.73. In terms of profitability, JAZZ's ROE is +0.21%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, JAZZ is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check MRNA's competition here
BioNTech SE (NASDAQ: BNTX)
JAZZ vs BNTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while BNTX trades at $114.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas BNTX's P/E ratio is -16.58. In terms of profitability, JAZZ's ROE is +0.21%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, JAZZ is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
JAZZ vs UTHR Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while UTHR trades at $525.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas UTHR's P/E ratio is 18.54. In terms of profitability, JAZZ's ROE is +0.21%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, JAZZ is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
JAZZ vs GMAB Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, GMAB has a market cap of 20.2B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while GMAB trades at $33.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas GMAB's P/E ratio is 24.84. In terms of profitability, JAZZ's ROE is +0.21%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, JAZZ is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
JAZZ vs BGNE Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas BGNE's P/E ratio is -22.55. In terms of profitability, JAZZ's ROE is +0.21%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, JAZZ is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
JAZZ vs DNA-WT Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, JAZZ's ROE is +0.21%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, JAZZ is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check DNA-WT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
JAZZ vs BBIO Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, BBIO has a market cap of 15.6B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while BBIO trades at $84.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas BBIO's P/E ratio is -21.36. In terms of profitability, JAZZ's ROE is +0.21%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, JAZZ is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BBIO's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
JAZZ vs NBIX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, NBIX has a market cap of 15.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while NBIX trades at $155.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas NBIX's P/E ratio is 22.29. In terms of profitability, JAZZ's ROE is +0.21%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, JAZZ is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
JAZZ vs ASND Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ASND has a market cap of 15.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ASND trades at $253.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ASND's P/E ratio is -102.83. In terms of profitability, JAZZ's ROE is +0.21%, compared to ASND's ROE of +1.90%. Regarding short-term risk, JAZZ is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
JAZZ vs EXEL Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, EXEL has a market cap of 13.4B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while EXEL trades at $54.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas EXEL's P/E ratio is 15.18. In terms of profitability, JAZZ's ROE is +0.21%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, JAZZ is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
JAZZ vs BMRN Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while BMRN trades at $68.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas BMRN's P/E ratio is 32.04. In terms of profitability, JAZZ's ROE is +0.21%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, JAZZ is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
JAZZ vs KRTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas KRTX's P/E ratio is -28.09. In terms of profitability, JAZZ's ROE is +0.21%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, JAZZ is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
JAZZ vs HALO Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, HALO has a market cap of 12.4B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while HALO trades at $106.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas HALO's P/E ratio is 19.57. In terms of profitability, JAZZ's ROE is +0.21%, compared to HALO's ROE of +1.81%. Regarding short-term risk, JAZZ is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check HALO's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
JAZZ vs ARWR Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ARWR has a market cap of 12.4B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ARWR trades at $88.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ARWR's P/E ratio is -39.07. In terms of profitability, JAZZ's ROE is +0.21%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, JAZZ is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
JAZZ vs MDGL Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while MDGL trades at $538.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas MDGL's P/E ratio is -40.97. In terms of profitability, JAZZ's ROE is +0.21%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, JAZZ is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
JAZZ vs TECH Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while TECH trades at $72.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas TECH's P/E ratio is 37.23. In terms of profitability, JAZZ's ROE is +0.21%, compared to TECH's ROE of +0.09%. Regarding short-term risk, JAZZ is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
JAZZ vs RNAM Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas RNAM's P/E ratio is -17.39. In terms of profitability, JAZZ's ROE is +0.21%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, JAZZ is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
JAZZ vs AXSM Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, AXSM has a market cap of 11.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while AXSM trades at $219.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas AXSM's P/E ratio is -56.32. In terms of profitability, JAZZ's ROE is +0.21%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, JAZZ is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check AXSM's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
JAZZ vs PRAX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, PRAX has a market cap of 10.3B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while PRAX trades at $371.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas PRAX's P/E ratio is -28.60. In terms of profitability, JAZZ's ROE is +0.21%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, JAZZ is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PRAX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
JAZZ vs SMMT Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while SMMT trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas SMMT's P/E ratio is -8.01. In terms of profitability, JAZZ's ROE is +0.21%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, JAZZ is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check SMMT's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
JAZZ vs PTGX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, PTGX has a market cap of 10.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while PTGX trades at $158.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas PTGX's P/E ratio is 152.76. In terms of profitability, JAZZ's ROE is +0.21%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, JAZZ is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
JAZZ vs KYMR Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, KYMR has a market cap of 10B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while KYMR trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas KYMR's P/E ratio is -37.93. In terms of profitability, JAZZ's ROE is +0.21%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, JAZZ is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check KYMR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
JAZZ vs IONS Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, IONS has a market cap of 9.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while IONS trades at $60.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas IONS's P/E ratio is -34.66. In terms of profitability, JAZZ's ROE is +0.21%, compared to IONS's ROE of -1.11%. Regarding short-term risk, JAZZ is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check IONS's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
JAZZ vs KRYS Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while KRYS trades at $343.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas KRYS's P/E ratio is 41.71. In terms of profitability, JAZZ's ROE is +0.21%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, JAZZ is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
JAZZ vs RXDX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas RXDX's P/E ratio is -56.47. In terms of profitability, JAZZ's ROE is +0.21%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, JAZZ is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check RXDX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
JAZZ vs CYTK Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CYTK has a market cap of 9.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CYTK trades at $76.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CYTK's P/E ratio is -12.26. In terms of profitability, JAZZ's ROE is +0.21%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, JAZZ is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CYTK's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
JAZZ vs SYRE Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, SYRE has a market cap of 9.4B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while SYRE trades at $107.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas SYRE's P/E ratio is -55.29. In terms of profitability, JAZZ's ROE is +0.21%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, JAZZ is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
JAZZ vs IMVT Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, IMVT has a market cap of 9.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while IMVT trades at $45.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas IMVT's P/E ratio is -15.71. In terms of profitability, JAZZ's ROE is +0.21%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, JAZZ is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check IMVT's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
JAZZ vs NUVL Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas NUVL's P/E ratio is -21.79. In terms of profitability, JAZZ's ROE is +0.21%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, JAZZ is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
JAZZ vs CRNX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CRNX trades at $84.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CRNX's P/E ratio is -16.81. In terms of profitability, JAZZ's ROE is +0.21%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, JAZZ is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CRNX's competition here
Abivax S.A. (NASDAQ: ABVX)
JAZZ vs ABVX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ABVX trades at $120.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ABVX's P/E ratio is -62.35. In terms of profitability, JAZZ's ROE is +0.21%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, JAZZ is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ABVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
JAZZ vs IMGN Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas IMGN's P/E ratio is -111.55. In terms of profitability, JAZZ's ROE is +0.21%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, JAZZ is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check IMGN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
JAZZ vs PCVX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while PCVX trades at $62.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas PCVX's P/E ratio is -7.84. In terms of profitability, JAZZ's ROE is +0.21%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, JAZZ is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
JAZZ vs BPMC Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas BPMC's P/E ratio is -51.58. In terms of profitability, JAZZ's ROE is +0.21%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, JAZZ is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
JAZZ vs APGE Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while APGE trades at $134.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas APGE's P/E ratio is -31.08. In terms of profitability, JAZZ's ROE is +0.21%, compared to APGE's ROE of -0.30%. Regarding short-term risk, JAZZ is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
JAZZ vs ALKS Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ALKS has a market cap of 8.3B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ALKS trades at $50.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ALKS's P/E ratio is 52.08. In terms of profitability, JAZZ's ROE is +0.21%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, JAZZ is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
JAZZ vs CERE Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CERE's P/E ratio is -16.47. In terms of profitability, JAZZ's ROE is +0.21%, compared to CERE's ROE of -0.72%. Regarding short-term risk, JAZZ is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
JAZZ vs IBRX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, IBRX has a market cap of 8.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while IBRX trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas IBRX's P/E ratio is -7.96. In terms of profitability, JAZZ's ROE is +0.21%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, JAZZ is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
JAZZ vs RYTM Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while RYTM trades at $117.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas RYTM's P/E ratio is -37.06. In terms of profitability, JAZZ's ROE is +0.21%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, JAZZ is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check RYTM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
JAZZ vs TGTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, TGTX has a market cap of 7.7B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while TGTX trades at $51.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas TGTX's P/E ratio is 18.21. In terms of profitability, JAZZ's ROE is +0.21%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, JAZZ is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check TGTX's competition here
Metsera, Inc. (NASDAQ: MTSR)
JAZZ vs MTSR Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas MTSR's P/E ratio is -23.58. In terms of profitability, JAZZ's ROE is +0.21%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, JAZZ is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
JAZZ vs MRUS Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas MRUS's P/E ratio is -17.05. In terms of profitability, JAZZ's ROE is +0.21%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, JAZZ is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check MRUS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
JAZZ vs ORKA Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ORKA has a market cap of 6.8B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ORKA trades at $111.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ORKA's P/E ratio is -58.29. In terms of profitability, JAZZ's ROE is +0.21%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, JAZZ is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ORKA's competition here
Arcellx, Inc. (NASDAQ: ACLX)
JAZZ vs ACLX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ACLX's P/E ratio is -28.27. In terms of profitability, JAZZ's ROE is +0.21%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, JAZZ is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
JAZZ vs CGON Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CGON has a market cap of 6.7B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CGON trades at $79.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CGON's P/E ratio is -28.36. In terms of profitability, JAZZ's ROE is +0.21%, compared to CGON's ROE of -0.25%. Regarding short-term risk, JAZZ is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
JAZZ vs RETA Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas RETA's P/E ratio is -66.29. In terms of profitability, JAZZ's ROE is +0.21%, compared to RETA's ROE of +0.47%. Regarding short-term risk, JAZZ is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check RETA's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
JAZZ vs SRRK Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while SRRK trades at $55.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas SRRK's P/E ratio is -15.86. In terms of profitability, JAZZ's ROE is +0.21%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, JAZZ is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check SRRK's competition here
Belite Bio, Inc (NASDAQ: BLTE)
JAZZ vs BLTE Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while BLTE trades at $165.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas BLTE's P/E ratio is -87.28. In terms of profitability, JAZZ's ROE is +0.21%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, JAZZ is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BLTE's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
JAZZ vs DNTH Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, DNTH has a market cap of 6.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while DNTH trades at $114.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas DNTH's P/E ratio is -27.84. In terms of profitability, JAZZ's ROE is +0.21%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, JAZZ is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
JAZZ vs COGT Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, COGT has a market cap of 6.4B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while COGT trades at $37.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas COGT's P/E ratio is -17.73. In terms of profitability, JAZZ's ROE is +0.21%, compared to COGT's ROE of -0.73%. Regarding short-term risk, JAZZ is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check COGT's competition here
Erasca, Inc. (NASDAQ: ERAS)
JAZZ vs ERAS Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ERAS trades at $18.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ERAS's P/E ratio is -19.46. In terms of profitability, JAZZ's ROE is +0.21%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, JAZZ is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ERAS's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
JAZZ vs CNTA Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CNTA's P/E ratio is -22.63. In terms of profitability, JAZZ's ROE is +0.21%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, JAZZ is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
JAZZ vs MIRM Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while MIRM trades at $103.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas MIRM's P/E ratio is -6.93. In terms of profitability, JAZZ's ROE is +0.21%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, JAZZ is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check MIRM's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
JAZZ vs DFTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, DFTX has a market cap of 6.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while DFTX trades at $45.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas DFTX's P/E ratio is N/A. In terms of profitability, JAZZ's ROE is +0.21%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, JAZZ is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check DFTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
JAZZ vs XENE Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while XENE trades at $63.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas XENE's P/E ratio is -13.44. In terms of profitability, JAZZ's ROE is +0.21%, compared to XENE's ROE of -0.44%. Regarding short-term risk, JAZZ is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check XENE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
JAZZ vs PTCT Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while PTCT trades at $72.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas PTCT's P/E ratio is -31.17. In terms of profitability, JAZZ's ROE is +0.21%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, JAZZ is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PTCT's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
JAZZ vs TVTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, TVTX has a market cap of 5.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while TVTX trades at $64.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas TVTX's P/E ratio is -142.00. In terms of profitability, JAZZ's ROE is +0.21%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, JAZZ is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check TVTX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
JAZZ vs CAI Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CAI has a market cap of 5.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CAI trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CAI's P/E ratio is 58.92. In terms of profitability, JAZZ's ROE is +0.21%, compared to CAI's ROE of +0.19%. Regarding short-term risk, JAZZ is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CAI's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
JAZZ vs LGND Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while LGND trades at $286.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas LGND's P/E ratio is 31.57. In terms of profitability, JAZZ's ROE is +0.21%, compared to LGND's ROE of +0.20%. Regarding short-term risk, JAZZ is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
JAZZ vs CDTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CDTX's P/E ratio is -19.77. In terms of profitability, JAZZ's ROE is +0.21%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, JAZZ is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
JAZZ vs ABCM Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, JAZZ's ROE is +0.21%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, JAZZ is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
JAZZ vs ISEE Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ISEE's P/E ratio is -22.44. In terms of profitability, JAZZ's ROE is +0.21%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, JAZZ is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
JAZZ vs APLS Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas APLS's P/E ratio is 38.35. In terms of profitability, JAZZ's ROE is +0.21%, compared to APLS's ROE of +0.40%. Regarding short-term risk, JAZZ is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
JAZZ vs ACAD Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ACAD has a market cap of 5.2B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ACAD trades at $30.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ACAD's P/E ratio is 14.65. In terms of profitability, JAZZ's ROE is +0.21%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, JAZZ is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ACAD's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
JAZZ vs CRSP Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CRSP trades at $57.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CRSP's P/E ratio is -11.13. In terms of profitability, JAZZ's ROE is +0.21%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, JAZZ is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CRSP's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
JAZZ vs DYN Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while DYN trades at $26.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas DYN's P/E ratio is -8.07. In terms of profitability, JAZZ's ROE is +0.21%, compared to DYN's ROE of -0.64%. Regarding short-term risk, JAZZ is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
JAZZ vs TERN Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas TERN's P/E ratio is -51.41. In terms of profitability, JAZZ's ROE is +0.21%, compared to TERN's ROE of -0.20%. Regarding short-term risk, JAZZ is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
JAZZ vs EWTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, EWTX has a market cap of 4.7B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while EWTX trades at $46.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas EWTX's P/E ratio is -23.84. In terms of profitability, JAZZ's ROE is +0.21%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, JAZZ is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check EWTX's competition here
Veradermics, Incorporated (NYSE: MANE)
JAZZ vs MANE Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while MANE trades at $114.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas MANE's P/E ratio is -35.50. In terms of profitability, JAZZ's ROE is +0.21%, compared to MANE's ROE of -0.29%. Regarding short-term risk, JAZZ is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check MANE's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
JAZZ vs PBLS Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while PBLS trades at $39.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas PBLS's P/E ratio is -44.72. In terms of profitability, JAZZ's ROE is +0.21%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, JAZZ is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
JAZZ vs FOLD Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas FOLD's P/E ratio is -161.00. In terms of profitability, JAZZ's ROE is +0.21%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, JAZZ is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check FOLD's competition here
Celcuity Inc. (NASDAQ: CELC)
JAZZ vs CELC Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CELC trades at $95.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CELC's P/E ratio is -21.68. In terms of profitability, JAZZ's ROE is +0.21%, compared to CELC's ROE of -3.51%. Regarding short-term risk, JAZZ is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CELC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
JAZZ vs RLAY Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, RLAY has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while RLAY trades at $20.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas RLAY's P/E ratio is -13.13. In terms of profitability, JAZZ's ROE is +0.21%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, JAZZ is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check RLAY's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
JAZZ vs AKRO Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas AKRO's P/E ratio is -14.57. In terms of profitability, JAZZ's ROE is +0.21%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, JAZZ is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
JAZZ vs ALPN Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ALPN's P/E ratio is -101.52. In terms of profitability, JAZZ's ROE is +0.21%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, JAZZ is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
JAZZ vs ELVN Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ELVN has a market cap of 4.3B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ELVN trades at $59.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ELVN's P/E ratio is -35.97. In terms of profitability, JAZZ's ROE is +0.21%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, JAZZ is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
JAZZ vs OPT Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas OPT's P/E ratio is -1.52. In terms of profitability, JAZZ's ROE is +0.21%, compared to OPT's ROE of +1.18%. Regarding short-term risk, JAZZ is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
JAZZ vs PRTC Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas PRTC's P/E ratio is -3.78. In terms of profitability, JAZZ's ROE is +0.21%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, JAZZ is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PRTC's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
JAZZ vs TNGX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while TNGX trades at $26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas TNGX's P/E ratio is -30.65. In terms of profitability, JAZZ's ROE is +0.21%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, JAZZ is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check TNGX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
JAZZ vs MRTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas MRTX's P/E ratio is -4.82. In terms of profitability, JAZZ's ROE is +0.21%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, JAZZ is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check MRTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
JAZZ vs LEGN Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while LEGN trades at $22.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas LEGN's P/E ratio is -32.24. In terms of profitability, JAZZ's ROE is +0.21%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, JAZZ is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check LEGN's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
JAZZ vs TLX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while TLX trades at $12.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas TLX's P/E ratio is -645.65. In terms of profitability, JAZZ's ROE is +0.21%, compared to TLX's ROE of -0.02%. Regarding short-term risk, JAZZ is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check TLX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
JAZZ vs ADPT Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while ADPT trades at $25.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas ADPT's P/E ratio is -59.90. In terms of profitability, JAZZ's ROE is +0.21%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, JAZZ is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ADPT's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
JAZZ vs AMLX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, AMLX has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while AMLX trades at $38.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas AMLX's P/E ratio is -23.41. In terms of profitability, JAZZ's ROE is +0.21%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, JAZZ is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check AMLX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
JAZZ vs VKTX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while VKTX trades at $34.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas VKTX's P/E ratio is -8.06. In terms of profitability, JAZZ's ROE is +0.21%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, JAZZ is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
JAZZ vs DNLI Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while DNLI trades at $25.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas DNLI's P/E ratio is -8.44. In terms of profitability, JAZZ's ROE is +0.21%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, JAZZ is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check DNLI's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
JAZZ vs CPRX Comparison August 2026
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JAZZ stands at 15.9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $253.03 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JAZZ currently has a P/E ratio of 9.44, whereas CPRX's P/E ratio is 12.30. In terms of profitability, JAZZ's ROE is +0.21%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, JAZZ is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CPRX's competition here